SCHEMBL1342825

SCHEMBL1342825

CS(=O)(=O)NCc1csc(NC(=O)C(=O)Nc2ccccc2C(=O)C2CCCC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.45
NPC1 O15118 4/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 2/20 0.38
ADORA3 P0DMS8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
HPGD P15428 3/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
KDM4E B2RXH2 3/20 0.37
CTPS1 P17812 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GAA P10253 1/20 0.36
SCD O00767 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1343156 0.91 RAB9A (0.44) RAB9ANPC1LMNAMEN1HTT
SCHEMBL1343080 0.89 RAB9A (0.38) RAB9ANPC1LMNAMEN1HTT
SCHEMBL6692815 0.87 AVPR1B (0.42) RAB9ANPC1LMNAMEN1HTT
SCHEMBL1341995 0.82 CLK1 (0.37) LMNAHTTKMT2AALDH1A1SMN1; SMN2
SCHEMBL1341818 0.81 RORC (0.36) RAB9ANPC1LMNAMEN1KMT2A
SCHEMBL1342180 0.81 RORC (0.36) RAB9ANPC1LMNAALDH1A1SMN1; SMN2
SCHEMBL1342591 0.81 SMN1; SMN2 (0.39) RAB9ANPC1LMNAMEN1HTT
SCHEMBL1340537 0.80 RORC (0.36) LMNAMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1343535 0.78 GRM4 (0.35) RAB9ALMNAHTTKMT2AALDH1A1
SCHEMBL1343578 0.77 GAA (0.43) RAB9ANPC1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
EP-1531815-A1 GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2005-05-25 EP disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed
WO-2004002481-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS NOVO NORDISK A/S (DK) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 RAB9A 3353/4885NPC1 2201/4885LMNA 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.